Cargando…

Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus for which no known effective antiviral drugs are available. In the present study, to accelerate the discovery of potential drug candidates, bioinformatics-based in silico drug discovery approaches are utilized. We pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Lokesh, Poullikkas, Thanasis, Eisenhower, Scott, Monsanto, Carlo, Bakku, Ranjith Kumar, Chen, Min-Hua, Kalra, Rajkumar Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839017/
https://www.ncbi.nlm.nih.gov/pubmed/33440681
http://dx.doi.org/10.3390/antib10010003
_version_ 1783643313633492992
author Agrawal, Lokesh
Poullikkas, Thanasis
Eisenhower, Scott
Monsanto, Carlo
Bakku, Ranjith Kumar
Chen, Min-Hua
Kalra, Rajkumar Singh
author_facet Agrawal, Lokesh
Poullikkas, Thanasis
Eisenhower, Scott
Monsanto, Carlo
Bakku, Ranjith Kumar
Chen, Min-Hua
Kalra, Rajkumar Singh
author_sort Agrawal, Lokesh
collection PubMed
description SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus for which no known effective antiviral drugs are available. In the present study, to accelerate the discovery of potential drug candidates, bioinformatics-based in silico drug discovery approaches are utilized. We performed multiple sequence alignments of the Spike (S) protein with 75 sequences of different viruses from the Orthocoronavirinae subfamily. This provided us with insights into the evolutionarily conserved domains that can be targeted using drugs or specific antibodies. Further, we analyzed the mechanism of SARS-CoV-2 core proteins, i.e., S and RdRp (RNA-dependent RNA polymerase), to elucidate how the virus infection can utilize hemoglobin to decrease the blood oxygen level. Moreover, after a comprehensive literature survey, more than 60 antiviral drugs were chosen. The candidate drugs were then ranked based on their potential to interact with the Spike and RdRp proteins of SARS-CoV-2. The present multidimensional study further advances our understanding of the novel viral molecular targets and potential of computational approaches for therapeutic assessments. The present study can be a steppingstone in the selection of potential drug candidates to be used either as a treatment or as a reference point when designing a new drug/antibody/inhibitory peptide/vaccine against SARS-CoV-2.
format Online
Article
Text
id pubmed-7839017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78390172021-01-28 Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets Agrawal, Lokesh Poullikkas, Thanasis Eisenhower, Scott Monsanto, Carlo Bakku, Ranjith Kumar Chen, Min-Hua Kalra, Rajkumar Singh Antibodies (Basel) Article SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus for which no known effective antiviral drugs are available. In the present study, to accelerate the discovery of potential drug candidates, bioinformatics-based in silico drug discovery approaches are utilized. We performed multiple sequence alignments of the Spike (S) protein with 75 sequences of different viruses from the Orthocoronavirinae subfamily. This provided us with insights into the evolutionarily conserved domains that can be targeted using drugs or specific antibodies. Further, we analyzed the mechanism of SARS-CoV-2 core proteins, i.e., S and RdRp (RNA-dependent RNA polymerase), to elucidate how the virus infection can utilize hemoglobin to decrease the blood oxygen level. Moreover, after a comprehensive literature survey, more than 60 antiviral drugs were chosen. The candidate drugs were then ranked based on their potential to interact with the Spike and RdRp proteins of SARS-CoV-2. The present multidimensional study further advances our understanding of the novel viral molecular targets and potential of computational approaches for therapeutic assessments. The present study can be a steppingstone in the selection of potential drug candidates to be used either as a treatment or as a reference point when designing a new drug/antibody/inhibitory peptide/vaccine against SARS-CoV-2. MDPI 2021-01-11 /pmc/articles/PMC7839017/ /pubmed/33440681 http://dx.doi.org/10.3390/antib10010003 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Agrawal, Lokesh
Poullikkas, Thanasis
Eisenhower, Scott
Monsanto, Carlo
Bakku, Ranjith Kumar
Chen, Min-Hua
Kalra, Rajkumar Singh
Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
title Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
title_full Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
title_fullStr Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
title_full_unstemmed Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
title_short Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets
title_sort viroinformatics-based analysis of sars-cov-2 core proteins for potential therapeutic targets
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839017/
https://www.ncbi.nlm.nih.gov/pubmed/33440681
http://dx.doi.org/10.3390/antib10010003
work_keys_str_mv AT agrawallokesh viroinformaticsbasedanalysisofsarscov2coreproteinsforpotentialtherapeutictargets
AT poullikkasthanasis viroinformaticsbasedanalysisofsarscov2coreproteinsforpotentialtherapeutictargets
AT eisenhowerscott viroinformaticsbasedanalysisofsarscov2coreproteinsforpotentialtherapeutictargets
AT monsantocarlo viroinformaticsbasedanalysisofsarscov2coreproteinsforpotentialtherapeutictargets
AT bakkuranjithkumar viroinformaticsbasedanalysisofsarscov2coreproteinsforpotentialtherapeutictargets
AT chenminhua viroinformaticsbasedanalysisofsarscov2coreproteinsforpotentialtherapeutictargets
AT kalrarajkumarsingh viroinformaticsbasedanalysisofsarscov2coreproteinsforpotentialtherapeutictargets